The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 30, 2010

Filed:

Nov. 18, 2003
Applicants:

Charlotte Albaek Thrue, Copenhagen K, DK;

Christoph Rosenbohm, Copenhagen NV, DK;

Henrik Frydenlund Hansen, Rødovre, DK;

Majken Westergaard, Birkerod, DK;

Nikolaj Dam Mikkelsen, Bronshoj, DK;

Signe M. Christensen, Copenhagen K, DK;

Troels Koch, Copenhagen S, DK;

Daniel Sejer Pedersen, Cambridge, GB;

Miriam Frieden, Copenhagen, DK;

Inventors:

Charlotte Albaek Thrue, Copenhagen K, DK;

Christoph Rosenbohm, Copenhagen NV, DK;

Henrik Frydenlund Hansen, Rødovre, DK;

Majken Westergaard, Birkerod, DK;

Nikolaj Dam Mikkelsen, Bronshoj, DK;

Signe M. Christensen, Copenhagen K, DK;

Troels Koch, Copenhagen S, DK;

Daniel Sejer Pedersen, Cambridge, GB;

Miriam Frieden, Copenhagen, DK;

Assignee:

Santaris Pharma A/S, Horsholm, unknown;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2006.01); A61K 31/70 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention is directed to novel oligonucleotides with improved antisense properties. The novel oligonucleotides comprise at least one Locked Nucleic Acid (LNA) selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides. The present invention also provides a new class of pharmaceuticals which comprise antisense oligonucleotides and are useful in antisense therapy.


Find Patent Forward Citations

Loading…